MediciNova is a biopharmaceutical company developing novel therapeutics for serious diseases with significant unmet medical needs, primarily targeting the U.S. market. The company's pipeline centers on two main compounds: MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in development for progressive multiple sclerosis, amyotrophic lateral sclerosis, degenerative cervical myelopathy, glioblastoma, and acute respiratory distress syndrome; and MN-001 (tipelukast), targeting fibrotic and metabolic disorders such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. MediciNova employs a hybrid development strategy combining investigator-sponsored trials, government-funded research, and company-sponsored clinical studies, while outsourcing manufacturing to third-party contractors and relying on strategic partnerships for future commercialization rather than building its own sales organization.